Huayao Kangming Biological

Huayao Kangmin Biological is a clinical-stage biotechnology company headquartered in Beijing, China, focused on the development of innovative oncolytic virus therapies for cancer treatment. The company leverages a proprietary poxvirus engineering platform to create recombinant viruses designed to selectively replicate in tumor cells and induce potent anti-tumor immunity. Its lead program, KM1, is a genetically modified vaccinia virus currently undergoing Phase 1 clinical evaluation for the treatment of advanced solid tumors. Huayao Kangmin's approach combines direct viral oncolysis with the expression of therapeutic transgenes to enhance the efficacy of existing immunotherapies. The company is backed by prominent venture capital firms and maintains a robust R&D pipeline targeting various hard-to-treat malignancies.